Andrew Arno
Andrew Arno's purchase track record
How the stock did after each of Andrew Arno's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/26/2024 | IMDX | $26K | +51.2% | +58.2% | +1.7% |
| 4/11/2024 | IMDX | $100K | +6.2% | +4.5% | +11.2% |
| 1/5/2024 | XXII | $17K | +23.6% | -76.5% | +18.5% |
| 12/23/2022 | IMDX | $88K | -31.6% | -47.4% | +13.1% |
| 8/17/2022 | SMSI | $99K | +0.9% | +41.1% | -3.0% |
| 8/15/2022 | IMDX | $158K | -57.7% | -53.6% | -3.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
SMSI Receives Rating Upgrade Amid Pre‑Market Moves. Smith Micro Software saw a rating upgrade from analysts, reflecting a more positive outlook. The stock also moved in pre‑market trading, showing increased interest ahead of the session. The upgrade aligns with the company’s recent performance and may influence market perception. Current technical levels show the price near its 52‑week low, indicating potential support.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
XXII's Reduced-Nicotine Platform Gains Attention in France. XXII has announced that its reduced‑nicotine tobacco platform aligns with France’s nicotine‑reduction policy. A study from France’s ANSES confirms the technology supports lower‑nicotine combustible products. Trading volume is higher than usual, suggesting growing interest. The stock sits near a low RSI, indicating it may be oversold.
Transaction History
| IMDX | ▼ Sell | Tax Withholding | 12,100 | $69K | 7/1/2026 | View on chart |
| IMDX | ▲ Buy | Grant | 32,331 | $0 | 6/11/2026 | View on chart |
| SMSI | ▲ Buy | Grant | 12,500 | $0 | 3/9/2026 | View on chart |
| XXII | ▲ Buy | Grant | 17,295 | $0 | 11/10/2025 | View on chart |
| SMSI | ▲ Buy | Grant | 7,993 | $0 | 10/9/2025 | View on chart |
| IMDX | ▲ Buy | Grant | 55,000 | $0 | 7/1/2025 | View on chart |
| XXII | ▲ Buy | Grant | 4,237 | $0 | 3/10/2025 | View on chart |
| SMSI | ▲ Buy | Grant | 25,000 | $0 | 1/23/2025 | View on chart |
| IMDX | ▲ Buy | Open Market | 12,500 | $26K | 12/26/2024 | View on chart |
| IMDX | ▲ Buy | Open Market | 33,898 | $100K | 4/11/2024 | View on chart |
| SMSI | ▲ Buy | Grant | 25,000 | $0 | 1/16/2024 | View on chart |
| XXII | ▲ Buy | Open Market | 100,000 | $17K | 1/5/2024 | View on chart |
| IMDX | ▲ Buy | Grant | 30,000 | $0 | 6/23/2023 | View on chart |
| IMDX | ▲ Buy | Grant | 141,084 | $50K | 4/3/2023 | View on chart |
| IMDX | ▲ Buy | Grant | 141,084 | $50K | 4/3/2023 | View on chart |
| IMDX | ▲ Buy | Grant | 141,084 | $50K | 4/3/2023 | View on chart |
| SMSI | ▲ Buy | Grant | 25,000 | $0 | 1/27/2023 | View on chart |
| IMDX | ▲ Buy | Open Market | 250,000 | $88K | 12/23/2022 | View on chart |
| SMSI | ▲ Buy | Open Market | 2,500 | $5K | 8/22/2022 | View on chart |
| IMDX | ▲ Buy | Open Market | 7,500 | $7K | 8/17/2022 | View on chart |
| IMDX | ▲ Buy | Open Market | 7,500 | $7K | 8/17/2022 | View on chart |
| SMSI | ▲ Buy | Open Market | 5,000 | $12K | 8/17/2022 | View on chart |
| SMSI | ▲ Buy | Open Market | 5,000 | $12K | 8/17/2022 | View on chart |
| SMSI | ▲ Buy | Open Market | 5,000 | $12K | 8/17/2022 | View on chart |
| SMSI | ▲ Buy | Open Market | 25,000 | $59K | 8/17/2022 | View on chart |
| IMDX | ▲ Buy | Open Market | 115,523 | $112K | 8/16/2022 | View on chart |
| IMDX | ▲ Buy | Grant | 10,000 | $0 | 8/15/2022 | View on chart |
| IMDX | ▲ Buy | Open Market | 34,477 | $32K | 8/15/2022 | View on chart |
| IMDX | ▲ Buy | Option Exercise | 10,000 | $0 | 6/24/2022 | View on chart |
| SMSI | ▲ Buy | Grant | 25,000 | $0 | 1/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
iMDx Amends Chronix Merger Deal Terms
Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.
iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.